Search Results

There are 33270 results for: content related to: Why have we failed to achieve neuroprotection in Parkinson's disease?

  1. Milestones in Parkinson's disease therapeutics

    Movement Disorders

    Volume 26, Issue 6, May 2011, Pages: 1072–1082, Olivier Rascol, Andres Lozano, Matthew Stern and Werner Poewe

    Version of Record online : 27 MAY 2011, DOI: 10.1002/mds.23714

  2. Therapeutic prospects for Parkinson disease

    Annals of Neurology

    Volume 74, Issue 3, September 2013, Pages: 337–347, C. Warren Olanow and Anthony H. V. Schapira

    Version of Record online : 9 OCT 2013, DOI: 10.1002/ana.24011

  3. Cell Transplantation and Gene Therapy in Parkinson's Disease

    Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine

    Volume 78, Issue 1, January/February 2011, Pages: 126–158, Dustin R. Wakeman, Hemraj B. Dodiya and Jeffrey H. Kordower

    Version of Record online : 21 JAN 2011, DOI: 10.1002/msj.20233

  4. The significance of defining preclinical or prodromal Parkinson's disease

    Movement Disorders

    Volume 27, Issue 5, 15 April 2012, Pages: 666–669, C. Warren Olanow and José A. Obeso

    Version of Record online : 16 APR 2012, DOI: 10.1002/mds.25019

  5. Trial designs used to study neuroprotective therapy in Parkinson's disease

    Movement Disorders

    Volume 28, Issue 1, January 2013, Pages: 86–95, Anthony E. Lang, Eldad Melamed, Werner Poewe and Olivier Rascol

    Version of Record online : 23 AUG 2012, DOI: 10.1002/mds.24997

  6. Neuroprotection in Parkinson's disease: Clinical trials

    Annals of Neurology

    Volume 53, Issue S3, 2003, Pages: S87–S99, Fabrizio Stocchi and C. Warren Olanow

    Version of Record online : 24 MAR 2003, DOI: 10.1002/ana.10488

  7. You have free access to this content
    Pharmacological Therapy in Parkinson's Disease: Focus on Neuroprotection

    CNS Neuroscience & Therapeutics

    Volume 17, Issue 5, October 2011, Pages: 345–367, Zsigmond Tamas Kincses and Laszlo Vecsei

    Version of Record online : 23 APR 2010, DOI: 10.1111/j.1755-5949.2010.00150.x

  8. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

    Movement Disorders

    Volume 23, Issue 15, 15 November 2008, Pages: 2194–2201, C. Warren Olanow, Robert A. Hauser, Joseph Jankovic, William Langston, Anthony Lang, Werner Poewe, Eduardo Tolosa, Fabrizio Stocchi, Eldad Melamed, Eli Eyal and Olivier Rascol

    Version of Record online : 19 OCT 2008, DOI: 10.1002/mds.22218

  9. Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials

    Movement Disorders

    Volume 28, Issue 2, February 2013, Pages: 131–144, Lorraine V. Kalia, Jonathan M. Brotchie and Susan H. Fox

    Version of Record online : 5 DEC 2012, DOI: 10.1002/mds.25273

  10. Limitations of current Parkinson's disease therapy

    Annals of Neurology

    Volume 53, Issue S3, 2003, Pages: S3–S15, Olivier Rascol, Pierre Payoux, Fabienne Ory, Joaquim J. Ferreira, Christine Brefel-Courbon and Jean-Louis Montastruc

    Version of Record online : 24 MAR 2003, DOI: 10.1002/ana.10513

  11. Functional models of Parkinson's disease: A valuable tool in the development of novel therapies

    Annals of Neurology

    Volume 64, Issue S2, December 2008, Pages: S16–S29, Peter Jenner

    Version of Record online : 6 JAN 2009, DOI: 10.1002/ana.21489

  12. Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death

    Journal of Neuroscience Research

    Volume 54, Issue 5, 1 December 1998, Pages: 707–719, Hideyuki Sawada, Masakazu Ibi, Takeshi Kihara, Makoto Urushitani, Akinori Akaike and Shun Shimohama

    Version of Record online : 12 DEC 1998, DOI: 10.1002/(SICI)1097-4547(19981201)54:5<707::AID-JNR16>3.0.CO;2-T

  13. Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease

    Movement Disorders

    Volume 28, Issue 1, January 2013, Pages: 3–7, Fabrizio Stocchi and C. Warren Olanow

    Version of Record online : 6 FEB 2013, DOI: 10.1002/mds.25337

  14. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease

    Annals of Neurology

    Volume 53, Issue S3, 2003, Pages: S149–S159, Anthony H. V. Schapira and C. Warren Olanow

    Version of Record online : 24 MAR 2003, DOI: 10.1002/ana.10514

  15. You have free access to this content
    Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors

    British Journal of Pharmacology

    Volume 172, Issue 16, August 2015, Pages: 4200–4215, Ian F Harrison, William R Crum, Anthony C Vernon and David T Dexter

    Version of Record online : 8 JUL 2015, DOI: 10.1111/bph.13208

  16. Prospects for Neuroprotective Therapies that can Modulate Non-Dopaminergic Features in Parkinson's Disease

    Parkinson's Disease: Non-Motor and Non-Dopaminergic Features

    C. Warren Olanow, Anthony E. Lang, Pages: 455–461, 2011

    Published Online : 27 JUN 2011, DOI: 10.1002/9781444397970.ch39

  17. You have free access to this content
    Neuroprotection in Parkinson's Disease: a Realistic Goal?

    CNS Neuroscience & Therapeutics

    Volume 16, Issue 6, December 2010, Pages: 327–329, Salvatore Galati and Giuseppe Di Giovanni

    Version of Record online : 9 NOV 2010, DOI: 10.1111/j.1755-5949.2010.00206.x

  18. Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis-targeted, disease-modifying strategy

    Movement Disorders

    Volume 20, Issue S11, May 2005, Pages: S3–S10, C. Warren Olanow and Joseph Jankovic

    Version of Record online : 8 APR 2005, DOI: 10.1002/mds.20457

  19. Parkinson's Disease

    Standard Article

    Wiley Handbook of Current and Emerging Drug Therapies

    Published Online : 13 OCT 2006, DOI: 10.1002/9780470041000.cedt084

  20. You have free access to this content
    The Role of Glutathione in Dopaminergic Neuronal Survival

    Journal of Neurochemistry

    Volume 69, Issue 5, November 1997, Pages: 1850–1858, Ken Nakamura, Wenyi Wang and Un Jung Kang

    Version of Record online : 18 NOV 2002, DOI: 10.1046/j.1471-4159.1997.69051850.x